Reliance, Capri Global to acquire Mumbai’s SevenHills Hospital

Reliance Industries and Capri Global will acquire Mumbai’s 1,500-bed SevenHills Hospital, ending an eight-year impasse. The hospital will be converted into a not-for-profit entity, with funds infused via equity support.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jyVMDnm
via IFTTT

Read More

Drug misuse: Govt may curb 'Pregabalin' sales

The government is looking to control the sale of Pregabalin. This common medicine is being misused. The government wants to make sure it is only sold with a doctor's prescription. This move follows concerns raised by authorities. Pregabalin is used for pain and seizures. Stricter rules are being considered to prevent its misuse.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eR6UohJ
via IFTTT

Read More

S&P Global upgrades Biocon Biologics credit rating To 'BB+'

Biocon Biologics has received a credit rating upgrade from S&P Global Ratings. The company's long-term issuer credit rating is now 'BB+' with a stable outlook. This upgrade follows Biocon's simplification of its capital structure and reduction of debt. New product launches and industry trends are expected to support Biocon's earnings growth in the coming years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EBvlO6z
via IFTTT

Read More

India-EU trade deal: A tonic for pharma companies

India and the EU are set to eliminate tariffs on pharmaceutical products, a move expected to significantly benefit India's pharma industry by reducing input costs and improving access to advanced medicines. Experts believe this will enhance trade and collaboration, strengthening India's position in the EU market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HQSgTiI
via IFTTT

Read More

India's over-the-counter drugs market to hit Rs 98,000 crore by 2030: Report

An EY report estimated that India's OTC market, valued around Rs 47,000 crore in 2024, is projected to grow to Rs 98,000 crore around 13 per cent CAGR through 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cAKW5PH
via IFTTT

Read More

India-EU FTA to strengthen position of Indian formulations, medicines in EU

A new India-EU free trade agreement promises to boost Indian pharmaceutical exports. Lower tariffs will make Indian medicines more competitive in Europe. This deal also aims to improve access to affordable, high-quality medicines for Indian patients. Experts anticipate significant price reductions for advanced therapies in the coming years. The agreement strengthens trade and collaboration between the two regions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MNICFpz
via IFTTT

Read More

PRISM-PCI Conclave 2026 in Vapi highlights India’s evolving approach to heart care

The PRISM-PCI Conclave 2026 highlighted India's significant advancements in cardiac care, showcasing its evolution from a consumer to a contributor in medical technology innovation. The event emphasized precision-driven strategies and the growing role of home-grown technologies in addressing complex cardiovascular diseases, improving patient outcomes globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/noeyFjI
via IFTTT

Read More

Cipla plans deeper push in domestic market and chronic therapies over next 2–3 years

Cipla's incoming MD and CEO-designate, Achin Gupta, outlined a two-to-three-year strategy focusing on deepening the domestic market presence and pursuing selective inorganic growth and innovation. The company aims to strengthen its respiratory leadership and achieve similar dominance in cardiometabolic diseases and obesity, with a near-term focus on the GLP-1 weight-loss segment through its partnership with Eli Lilly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0Zv75Wb
via IFTTT

Read More

China halts sale of Sun Pharma drug used to treat dementia

China's medicine regulator has halted the import, sale, and use of Sun Pharmaceutical Industries' dementia drug, rivastigmine hydrogen tartrate capsules. A recent inspection revealed production process shortcomings, including contamination prevention and quality management issues. This follows a 2024 warning letter from the U.S. FDA regarding similar manufacturing practice violations at the same Indian site.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TwltGCH
via IFTTT

Read More

India’s 'Healthcare Budget' crossroads: Why the next leap is about design, not just spend

Union Budget 2026: India's healthcare system faces a structural shift from episodic care to lifelong management of chronic diseases. The Union Budget must move beyond incremental spending to architect a resilient system by addressing hospital capacity, insurance viability, human capital development, and digital health integration. A multi-year roadmap is crucial for long-term growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OsWbIHA
via IFTTT

Read More

Sun Pharma, Cipla recall products in US over manufacturing issues: USFDA

Sun Pharma and Cipla, two leading drug manufacturers from India, are taking precautionary measures by recalling products in the United States due to safety concerns. Sun Pharma's recall involves their generic skin condition treatments, identified to have impurity problems, while Cipla is addressing contamination in an injection linked to particulate matter. These recalls align with the oversight of the U.S.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dumaP6g
via IFTTT

Read More

Pitiless Cut: Blood money for a broken hip

India's Supreme Court has ordered Johnson & Johnson to pay more compensation for faulty hip implants. This decision comes after a long legal battle for justice for patients. The court's ruling fixes culpability on the global company. However, the compensation awarded to Indian patients is significantly less than what was given in the US. Many patients continue to seek relief.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/80I5azy
via IFTTT

Read More

Sun Pharma gets DCGI nod to launch generic semaglutide for weight management

Sun Pharma has gained the green light from the DCGI for its much-anticipated generic version of semaglutide injection, targeting chronic weight management under the name Noveltreat. With Novo Nordisk's patent expiration on the horizon, this initiative marks a pivotal moment in accessible healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9YVxW2L
via IFTTT

Read More

Sun Pharma gets DCGI nod for Wegovy-like weight loss drug, launch after Novo Nordisk's patent expiry

Sun Pharma has received DCGI approval to launch Noveltreat, a generic semaglutide injection for chronic weight management in India. This GLP-1 receptor agonist will be available after patent expiry, offering a crucial treatment option for India's growing obesity and diabetes burden. The approval follows successful Indian clinical trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ijY5MyZ
via IFTTT

Read More

New drugs could reach market sooner as govt halves trial review timeline

The Indian government is shaking up the pharmaceutical sector by slashing the review period for manufacturing applications for new drugs to 45 days. Now, manufacturers can initiate clinical trials or bioequivalence studies with just a prior notification to the regulators, ditching the old requirement for express permission.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Np3P9nl
via IFTTT

Read More

Bastar's first super-specialty hospital opens

Bastar region will soon have its first super specialty hospital. Located in Jagdalpur, the facility opens in February. Hyderabad-based Continental Hospitals partners with the Chhattisgarh government. This 240-bedded hospital will offer advanced medical services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4FoeWz6
via IFTTT

Read More

Budget 2026: Industry leaders seek funding framework for innovation, R&D in pharma, MedTech

Industry leaders are calling for a structured funding framework in the upcoming Union Budget. This aims to boost innovation and R&D in India's pharmaceutical and MedTech sectors. The goal is to drive advanced research and achieve the Viksit Bharat vision. Companies seek support for complex therapies and improved patient access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GsVdtYK
via IFTTT

Read More

Zydus launches biosimilar for treatment of multiple cancers

Zydus Lifesciences has launched Tishtha, the world's first biosimilar of Nivolumab, in India. This drug treats multiple cancers. Tishtha will be available in 100 mg and 40 mg dosages. The prices are significantly lower than the reference drug. This launch expands access to immuno-oncology therapies. The company aims to support patients with consistent care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mgIh9iF
via IFTTT

Read More

Over 160 drug samples found sub-standard in December

A recent inspection by India's drug regulator has revealed a troubling statistic: 167 medication samples were classified as not of standard quality (NSQ) in December, with valuable insights from both central and state laboratories aiding the findings. Many of these samples consisted of widely used drugs, highlighting a critical need for heightened quality control.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5euzjas
via IFTTT

Read More

CDSCO finds over 160 drug samples as 'not of standard quality' for December

In December 2025, 74 drug samples were identified as Not of Standard Quality (NSQ) by Central Drugs Laboratories and 93 by State Drugs Testing Laboratories. Additionally, seven spurious drug samples were identified across various zones, manufactured by unauthorized entities. These findings are part of routine regulatory surveillance to ensure market safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pmvjSGU
via IFTTT

Read More

Drug maker Lupin inks licensing pact with Galenicum for injectable Semaglutide

Drug maker Lupin announced a significant partnership. Its subsidiary, Lupin Atlantis Holdings SA, has signed an agreement with Galenicum Health. This collaboration focuses on diabetes and weight management medication, specifically injectable Semaglutide. Galenicum will handle development and manufacturing. Lupin will manage regulatory submissions, approvals, and commercialisation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z3k2BLK
via IFTTT

Read More

Delhi High Court denies interim protection to Alkem in 'A to Z' trademark case

The Delhi High Court has denied Alkem Laboratories interim protection in a trademark dispute. Prevego Healthcare & Research can continue selling its multivitamin product under the brand name Multivein AZ. Alkem Laboratories had claimed infringement of its A to Z and A to Z-NS trademarks. The court noted differences in fonts, color schemes, and trade dress.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RI5e2nz
via IFTTT

Read More

Novo Holdings buys 49% stake in Surya Hospitals

Novo Holdings, a major investment firm, has acquired a 49% stake in Surya Hospitals for an estimated Rs 1,000-1,200 crore. This strategic move highlights Novo Holdings' focus on specialized healthcare in India, particularly in women's and children's care, where Surya Hospitals has a strong reputation. The deal underscores the ongoing investment trend in the Indian hospital sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CTcglWU
via IFTTT

Read More

Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever

Sun Pharmaceutical Industries Ltd has submitted a non-binding offer to acquire US-based Organon for an all-cash deal, securing $10-14 billion in acquisition financing. This move marks Sun Pharma's boldest global bet, aiming to bolster its presence in women's health biopharma and biosimilars. The acquisition, if successful, would be the largest by an Indian pharmaceutical company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KSMml42
via IFTTT

Read More

Syngene expands research collaboration with Bristol Myers Squibb

Syngene International has extended its research partnership with Bristol Myers Squibb until 2035. This expanded agreement covers more services for drug development, from discovery to manufacturing. The collaboration, which began in 1998, will now focus on building new capabilities for future programs. This move aims to accelerate the delivery of new medicines to patients worldwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bXsF7u0
via IFTTT

Read More

Sun Pharma clarifies $10 bn Organon acquisition report, calls it 'speculative in nature'

Sun Pharma has addressed speculation regarding a potential $10 billion acquisition of US firm Organon. The Indian drugmaker stated the reports are speculative and no material event requires disclosure. Sun Pharma adheres to high governance standards. Organon, focused on women's health and biosimilars, was spun off from Merck in 2021.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PHUv1mE
via IFTTT

Read More

Sun Pharma looks to rise in US with $10 billion Organon buy

India's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based Organon, a specialist in women's health. This potential deal is valued at around $10 billion. A successful acquisition would be a significant move for Sun Pharma, strengthening its presence in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0h8sbam
via IFTTT

Read More

Brazil, Nigeria emerging as key export destinations for Indian pharmaceuticals

Indian pharmaceutical exports are seeing strong growth. Brazil and Nigeria are now important markets for Indian medicines. This shows a wider reach for Indian pharma products. The US remains the biggest buyer. Other countries like France and Germany are also increasing their purchases. This diversification strengthens India's position as a global medicine supplier.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YkUXJmF
via IFTTT

Read More

PE backed ASG Eye hires Morgan Stanley and three other bankers for upcoming IPO

ASG Hospital, a major eye care chain, is preparing for its initial public offering. The company has selected four investment banks to manage the process. ASG plans to raise between ₹3,000 and ₹4,000 crore. This offering is expected to take place in the financial year 2027. The move follows strong market interest in the healthcare sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lFGetrH
via IFTTT

Read More

IHCL to aquire 51% stake in Brij Hospitality

Indian Hotels Company, backed by Tata Group, is acquiring a majority stake in Brij Hospitality. This move aims to bolster IHCL's presence in the boutique luxury hotel market. The deal, valued at up to Rs 225 crore, will integrate Brij's portfolio of 22 hotels. This acquisition is expected to be completed by March 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vZXRDUS
via IFTTT

Read More

Zydus Lifesciences gets USFDA nod for generic blood disorder drug

Zydus Lifesciences has secured final approval from the USFDA for its generic Eltrombopag tablets. These tablets treat low platelet counts in specific blood disorders. The approval covers multiple strengths. Production will occur at the company's Ahmedabad facility. This development marks a significant step for Zydus in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rdIUcPe
via IFTTT

Read More

Delhi HC restores ban on 2 diabetes FDCs

The Delhi High Court has made waves with its recent judgment, reinstating a ban on two fixed-dose combination drugs for managing Type II Diabetes Mellitus, significantly affecting leading pharmaceutical corporations. The ruling reaffirmed the government's power to eliminate drugs deemed risky to health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aSpsy7h
via IFTTT

Read More

Dr Reddy's launches generic OTC ophthalmic solution in US market

Dr Reddy's Laboratories has launched a new eye drop in the United States. This over-the-counter solution treats itchy eyes. It is an antihistamine eye drop. The company received approval from the US Food and Drug Administration. This launch expands their existing eye care products. It highlights their ability to bring store-brand equivalents to the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ckLF6r3
via IFTTT

Read More

Indian hospital chain Narayana Health eyes international expansion

Narayana Hrudayalaya is gearing up to make its mark in Western healthcare markets. Leveraging its innovative, affordable healthcare model that has thrived in India, the company is now setting its sights on the UK as a strategic launchpad for further global expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ghdU8Wf
via IFTTT

Read More

Apollo Hospitals demerger is a biz call taken for shareholders, says Suneeta Reddy; rules out family rift

Apollo Hospitals MD Suneeta Reddy says the group’s restructuring is about business strategy, not family dynamics, aiming to unlock value by separating hospital and pharmacy-digital units. She stresses close ties with sister Shobana Kamineni, outlines expansion in metros and Tier-II cities, focus on preventive care, tech-led growth, and mentoring the next generation of leaders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KyNFkbC
via IFTTT

Read More

Biocon arm gets USFDA nod for generic Everolimus tablets

Biocon's arm, Biocon Pharma Ltd, has secured USFDA approval for its generic Everolimus tablets. This medication aids in treating tuberous sclerosis complex, a rare genetic disorder causing tumors. The approval for 2mg, 3mg, and 5mg strengths bolsters Biocon's drug offerings, providing a new treatment option for adult and pediatric patients with specific TSC-related conditions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fRySVtg
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA tentative nod for generic cancer treatment drug

Alembic Pharmaceuticals has secured tentative approval from the USFDA for its Bosutinib tablets. These tablets are used to treat certain types of cancer, specifically chronic myelogenous leukemia. The approval covers the 400 mg strength. This development marks a significant step for Alembic in the US market. The company previously received final approval for other strengths of the same drug.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rH46BXY
via IFTTT

Read More

Delhi HC clears Zydus to sell biosimilar of BMS cancer drug Nivolumab

The Delhi High Court has permitted Zydus Lifesciences to produce and market a biosimilar cancer drug. This decision comes as the patent for the original drug, Nivolumab, nears its expiration. The court prioritized patient access to affordable treatment. Zydus can now proceed with its biosimilar, ZRC-3276, while maintaining sales records.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1xJoX3t
via IFTTT

Read More

Budget 2026: Pharma, med-tech companies seek PLI extension to cover APIs

The industry expects the government to address these issues in the Union budget announcement this year. Sudarshan Jain, secretary general of Indian Pharmaceutical Alliance (IPA) said the recent global challenges like US tariffs, supply chain disruptions and geopolitical uncertainty have underscored the need for strategic support, and hence, restoring 200% weighted deduction for research and development expenditures would be a significant step.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OqjgdAW
via IFTTT

Read More

Aurobindo Pharma’s Dyrupeg faces Health Canada compliance notice

CuraTeQ Biologics, a part of Aurobindo Pharma, has secured a crucial approval from Health Canada for its biosimilar drug Dyrupeg. This medication helps cancer patients with low neutrophil counts. The approval confirms Dyrupeg's high similarity to an existing reference biologic drug. Earlier, Dyrupeg also gained marketing authorization in the European Union and the UK.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xyQkAH5
via IFTTT

Read More

Canadian pharmacy platform to offer India-sourced Ozempic to US patients

SaveRxCanada.to, an online pharmacy platform, announced it is now offering Ozempic sourced from India to U.S. patients at significantly lower prices than U.S. retail pharmacies. The company claims to connect patients with licensed international pharmacies, though Novo Nordisk denies any relationship with the platform.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/297GfUX
via IFTTT

Read More

Cardiac drugs log highest sales in 2025 as NCD cases surge

Heart medicines led sales in 2025, a trend set to continue. Respiratory and anti-diabetes drugs followed. Cardiac drug sales grew 13%, with similar strong performance expected. Rising non-communicable diseases like hypertension fuel this growth. Increased awareness and longer treatment durations contribute.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mNpRfx4
via IFTTT

Read More

Ayushman Bharat: UP cuts claim pendency sharply, speeds up hospital payments

Uttar Pradesh is making waves in healthcare with significant advancements in settling Ayushman Yojana claims. The state is firmly committed to timely reimbursements for partner hospitals, leading to a culture of transparency in claims processing. These initiatives have slashed the backlog of pending claims, ensuring that hospitals provide swift treatment to Ayushman card holders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0WOf5sY
via IFTTT

Read More

Granules India gets USFDA tentative nod for generic ADHD treatment tablets

Granules Pharmaceuticals, Inc., a subsidiary of Granules India, has achieved a significant milestone with the tentative green light from US health authorities for its generic amphetamine extended-release tablets, designed for managing attention deficit hyperactivity disorder.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/naEeM6W
via IFTTT

Read More

Future diabetes care seen leaning towards GLP-1 drugs

The diabetes treatment landscape in India is on the brink of transformation. Innovative GLP-1 medications are set to redefine therapy standards, providing remarkable advantages in glucose regulation and weight management, while also safeguarding vital organs such as the heart and kidneys.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x9NhIZo
via IFTTT

Read More

Budget 2026: Volume to value - How India can get a quiet superpower

India Budget: India's pharmaceutical industry, a global leader in volume, is poised to leverage its scale for greater international influence. The upcoming Union Budget 2026-27 presents a crucial opportunity to shift focus from low-margin generics to high-value segments like biologics and novel drug discovery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OEbw4tn
via IFTTT

Read More

HC seeks Novo Nordisk's reply on Natco plea to revoke patent

The Delhi High Court has asked Novo Nordisk to explain why its patent for the diabetes and weight loss drug semaglutide should not be cancelled. Natco Pharma filed the petition. Novo Nordisk's patent expires in March. This has sparked patent disputes as other companies aim to produce their own versions of the drug.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WFIrpbg
via IFTTT

Read More

Biocon Biologics to introduce three new biosimilars for cancer treatment

Biocon Biologics will launch three new oncology biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The company aims to expand access to vital cancer treatments. These biosimilars will offer cost-effective alternatives. Biocon Biologics will have one of the most comprehensive oncology portfolios. This move strengthens its commitment to patient care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f9msa6p
via IFTTT

Read More

Max Healthcare partners with The Learning Lab for advance healthcare capacity building, research

Max Healthcare has partnered with UK-based The Learning Lab to advance healthcare capacity-building and foster joint research. The collaboration will co-create training modules for healthcare professionals, aiming to strengthen clinical competencies and improve patient outcomes. This initiative combines Max Healthcare's clinical experience with The Learning Lab's educational expertise to deliver practical, evidence-based learning.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uA3vO4L
via IFTTT

Read More

IIT Roorkee hosts 'AHEAD 2025' global health conference

IIT Roorkee hosted the "AHEAD 2025" International Conference on Health and Development, bringing together global experts to address critical challenges. The event focused on policy-relevant research for health systems resilience, climate health, and demographic change, aligning with India's development agenda and SDGs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BZXKoE6
via IFTTT

Read More

Indian fertility experts advise caution on clinical use of new 'Non-Invasive' Embryo Genetic Test

Leading Indian fertility experts have cautioned against using non-invasive embryo genetic testing (niPGT) for routine clinical decisions. A joint review by ISAR, IFS, and ACE found the technique prone to high misdiagnosis rates, potentially leading to incorrect embryo selection or discarding. The technology, while promising, lacks sufficient evidence for clinical use.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y58haKj
via IFTTT

Read More

Budget for 'pharmacy of the world': What Sitharaman & Co can do to make medicines more affordable in India

Union Budget 2026: India's pharmaceutical landscape is on the brink of a transformative boom. To maintain this upward trajectory, the focus must shift towards fostering innovation and enhancing the efficiency of drug manufacturing. Strategic government funding is essential to bolster research initiatives, support production facilities, and strengthen healthcare frameworks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fv9FTCQ
via IFTTT

Read More